

MORPHINE**This drug must be guardrailed**

| Trade Name | IV: Morphine Sulphate injection B.P (DBL) Oral: RA – Morph (Pfizer) | | | | | | | | | | | | | | | | | | | | | | | | | | |
|--|--|--------------|-----------------------------------|------|-------------|--------------|---------------|--|----------------------|--|--|------------|------|-------|-----------|------|-------------|--------------|----------------------------|--|--|--|--|---------------|-----------------|-------|-----------------------------------|
| Class | Opiate analgesic | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Mechanism of Action | Stimulates brain opiate receptors. Releases histamine and centrally suppresses adrenergic tone, increasing venous capacitance. Alters perception of, and response to pain. | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Indications | Indication 1: Analgesia Indication 2: Sedation Indication 3: Dependence following long term infusion Indication 4: Treatment of opiate withdrawal Indication 5: Palliative care | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Contraindications | Hypersensitivity to morphine. Use with caution in patients with raised intracranial pressure, hepatic or renal impairment, hypotension or breathing difficulties. | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Supplied As | IV: Morphine sulphate 10mg in 1 mL for injection. Oral: Morphine hydrochloride solution 1mg/mL for oral use. | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Dilution... *TWO dilution steps required for IV infusion* | <ul style="list-style-type: none"> ▪ IV Infusion: See morphine iv infusion sheet <table border="1"> <thead> <tr> <th>Drug</th> <th>Add Diluent</th> <th>Total Volume</th> <th>Concentration</th> </tr> </thead> <tbody> <tr> <td></td> <td>0.9% sodium chloride</td> <td></td> <td></td> </tr> <tr> <td>10mg = 1mL</td> <td>9 mL</td> <td>10 mL</td> <td>1 mg / mL</td> </tr> </tbody> </table> <p>Step 2. Further dilute the 1 mg/mL solution in step 1</p> <table border="1"> <thead> <tr> <th>Drug</th> <th>Add Diluent</th> <th>Total Volume</th> <th>FINAL CONCENTRATION</th> </tr> </thead> <tbody> <tr> <td></td> <td>0.9% sodium chloride, 5% or 10% dextrose</td> <td></td> <td></td> </tr> <tr> <td>Wt (kg) in mL</td> <td>Make up to 50mL</td> <td>50 mL</td> <td>Varies depending on weight</td> </tr> </tbody> </table> <p>1mL/hr = 20 microgram/kg/hr . Maximum concentration to be ≤ 200 microgram/mL 1mL/hr = 40 microgram/kg/hr if double strength the infusion for babies <1kg</p> | | | Drug | Add Diluent | Total Volume | Concentration | | 0.9% sodium chloride | | | 10mg = 1mL | 9 mL | 10 mL | 1 mg / mL | Drug | Add Diluent | Total Volume | FINAL CONCENTRATION | | 0.9% sodium chloride, 5% or 10% dextrose | | | Wt (kg) in mL | Make up to 50mL | 50 mL | Varies depending on weight |
| Drug | Add Diluent | Total Volume | Concentration | | | | | | | | | | | | | | | | | | | | | | | | |
| | 0.9% sodium chloride | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 10mg = 1mL | 9 mL | 10 mL | 1 mg / mL | | | | | | | | | | | | | | | | | | | | | | | | |
| Drug | Add Diluent | Total Volume | FINAL CONCENTRATION | | | | | | | | | | | | | | | | | | | | | | | | |
| | 0.9% sodium chloride, 5% or 10% dextrose | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Wt (kg) in mL | Make up to 50mL | 50 mL | Varies depending on weight | | | | | | | | | | | | | | | | | | | | | | | | |

| <p>... Dilution</p> | <ul style="list-style-type: none"> ▪ Bolus Dose (if not bolusing from an existing infusion) <table border="1" data-bbox="512 208 1433 483"> <thead> <tr> <th data-bbox="512 208 730 277">Drug</th> <th data-bbox="730 208 957 277">Add Diluent</th> <th data-bbox="957 208 1110 277" rowspan="2">Total Volume</th> <th data-bbox="1110 208 1433 277" rowspan="2">Concentration</th> </tr> <tr> <td colspan="2" data-bbox="730 277 957 376">0.9% sodium chloride</td> </tr> </thead> <tbody> <tr> <td data-bbox="512 376 730 483">10mg = 1mL</td> <td data-bbox="730 376 957 483">9 mL</td> <td data-bbox="957 376 1110 483">10 mL</td> <td data-bbox="1110 376 1433 483">1 mg / mL</td> </tr> </tbody> </table> ▪ Subcutaneous Infusion: see separate subcutaneous infusion sheet | Drug | Add Diluent | Total Volume | Concentration | 0.9% sodium chloride | | 10mg = 1mL | 9 mL | 10 mL | 1 mg / mL |
|--|--|--------------|---------------|--------------|---------------|----------------------|--|------------|------|-------|-----------|
| Drug | Add Diluent | Total Volume | Concentration | | | | | | | | |
| 0.9% sodium chloride | | | | | | | | | | | |
| 10mg = 1mL | 9 mL | 10 mL | 1 mg / mL | | | | | | | | |
| <p>Dosage</p> <p>*Must chart guardrail and use Alaris pump for IV infusions*</p> | <p>IV Bolus: 25 or 50 microgram/kg/dose Can be given as a bolus from the continuous infusion on the guardrailed pumps or from a separately drawn up 1mg/mL solution If give >2 boluses in 24hrs consider increasing the infusion dose Monitor the fluid volume received from the boluses (1.25ml - 2.5mL at standard infusion concentration)</p> <p>100 microgram/kg/dose Use if immediate analgesia/ sedation is required Draw up a 1mg/mL solution to give this dose as the volume is too high if given directly from the infusion</p> <p>IV Infusion: 5-30 microgram/kg/hour Start at 10microgram/kg/hr for sedation while on mechanical ventilation. Higher rates in surgical cases</p> <p>Oral Dosing: 50 – 200 mcg/kg/dose every 4-6 hours 100mcg/kg/dose equates to about 5mcg/kg/hr iv and is a good starting option for most babies. Dose can be titrated up if needed. Lower starting dose of 50mcg/kg/dose may be better if there are concerns about respiratory state and sedation</p> <p>If Converting from IV: Daily dose is 4 times the daily iv dose Oral mcg/dose = $\frac{\text{iv dose (mcg/kg/hr)} \times \text{Wt (kg)} \times 24\text{hrs} \times 4}{\text{Number of oral doses per day (4 or 6 hourly)}}$</p> <p>Narcotic Abstinence Syndrome: See separate protocol</p> | | | | | | | | | | |
| <p>Guardrails</p> | <p>Conc: Min – 3 microgram/mL Max – 200 microgram/mL Soft Min: 2 microgram/kg/hr Hard Max: 60 microgram/kg/hr Soft Max: 30 microgram/kg/hr Default: 10 microgram/kg/hr</p> | | | | | | | | | | |
| <p>Guardrails Boluses</p> | <p>Default Rate: 50mL/hr – bolus will be given over 1.5-3 minutes at standard infusion concentration</p> <p>Soft Min: 10 microgram/kg Hard Max: 50 microgram/kg Soft Max: 50 microgram/kg Default: 25 microgram/kg</p> | | | | | | | | | | |

| | |
|--------------------------|---|
| Interval | Bolus dose: as required , dose can last 1-4 hours Infusion: continuous Oral: 4-6 hourly |
| Administration | IV, oral, subcutaneous |
| Compatible With | Solution: 5% and 10% dextrose, sodium chloride 0.9% Terminal Y-site: Acyclovir, adrenaline, alprostadil, amikacin, aminophylline, amiodarone, ampicillin, atropine, benzylpenicillin, calcium chloride, caspofungin, cefazolin, cefotaxime, ceftazidime, ceftriaxone, chloramphenicol, clindamycin, dexmedetomidine, dexamethasone, digoxin, dobutamine, dopamine, enalapril, erythromycin, fentanyl, fluconazole, furosemide, gentamicin, glycopyrrolate, heparin, insulin, hydrocortisone, hyoscine hydrobromide, lidocaine, linezolid, lorazepam, magnesium, meropenem, methylprednisolone, metoclopramide, metronidazole, midazolam, milrinone, naloxone, noradrenaline, pancuronium, paracetamol, phenobarbital, piperacillin/tazocactam, potassium chloride, propranolol, ranitidine, sodium bicarbonate, sodium nitroprusside, ticarcillin/clavulanate, tobramycin, TPN, trimethoprim/sulphamethoxazole, vancomycin, vecuronium, voriconazole, zidovudine. |
| Incompatible With | Aminophylline, azathioprine, azithromycin, flucloxacillin, folic acid, ganciclovir, indomethacin, phenytoin, thiopental. There is no information on compatibility of morphine with lipid solutions |
| Interactions | Morphine decreases effects of diuretics by inducing release of ADH. Morphine may increase zidovudine levels by competitively inhibiting glucuronidation or directly inhibiting metabolism. |
| Monitoring | Respiratory and cardiovascular status. Bowel and urinary output (especially at higher doses). |
| Stability | IV/Subcut: Discard opened vial immediately after use Use a new vial for each dose. Continuous infusions need to be changed after 24 hours Unused reconstituted 1mg/mL solution may be kept if repeated boluses may be required. <ul style="list-style-type: none"> • May be kept for the length of the shift of the nurse who drew up the drug and is caring for the patient • The syringe must be labelled with the name of the drug and the name of the patient and may be stored in the controlled drug safe. • Any morphine remaining in the syringe at the end of that nurse's shift should be discarded and if ongoing treatment is required a new syringe should be prepared by nursing staff on the next shift. |

| | | | | | | | | | | | | | | | | | |
|--------------------------|--|------------|-------------------------------------|--------------------------|---------------|-----------------------|----------------------------|-----------------------|---|--------|---------------------------------------|-----------------------|-------------------------------|-----------------------|-----------------------------|-----------------------|---|
| | <p>Oral: Open bottles of morphine mixture may be kept for 6months or the manufacturer's expiry whichever is shorter.</p> | | | | | | | | | | | | | | | | |
| Storage | Store below 25°C and in a controlled drug safe. Protect from light. Development of a yellow colour does not indicate toxicity, or loss of potency. | | | | | | | | | | | | | | | | |
| Adverse Reactions | Respiratory depression, bradycardia, hypotension, ileus and delayed gastric emptying, urinary retention, sweating, nausea and vomiting, development of tolerance. Seizures (higher or more rapid doses). Naloxone reverses effects. Mechanical ventilation may be preferable if narcotic effects required. | | | | | | | | | | | | | | | | |
| Comments | RA-Morph® is a clear colourless or pale yellow solution. It is sugar and alcohol free. | | | | | | | | | | | | | | | | |
| References | Neofax 2000, 1999 Medicines for Children RCPCH. ADC 2000;83:F101-3 | | | | | | | | | | | | | | | | |
| Updated By | <table> <tr> <td>K Simonsen</td> <td>Nov 2003 (calculation of oral dose)</td> </tr> <tr> <td>P Schmidt, B Robertshawe</td> <td>December 2004</td> </tr> <tr> <td>A Lynn, B Robertshawe</td> <td>September 2009 (guardrail)</td> </tr> <tr> <td>A Lynn, B Robertshawe</td> <td>Nov 2012 (re-order profile, discard vial)</td> </tr> <tr> <td>A Lynn</td> <td>May 2013/Aug 2015 (guardrail boluses)</td> </tr> <tr> <td>A Lynn, B Robertshawe</td> <td>October 2021 (routine review)</td> </tr> <tr> <td>A Lynn, B Robertshawe</td> <td>November 2022 (oral dosing)</td> </tr> <tr> <td>A Lynn, B Robertshawe</td> <td>March 2023 (double dilution instructions)</td> </tr> </table> | K Simonsen | Nov 2003 (calculation of oral dose) | P Schmidt, B Robertshawe | December 2004 | A Lynn, B Robertshawe | September 2009 (guardrail) | A Lynn, B Robertshawe | Nov 2012 (re-order profile, discard vial) | A Lynn | May 2013/Aug 2015 (guardrail boluses) | A Lynn, B Robertshawe | October 2021 (routine review) | A Lynn, B Robertshawe | November 2022 (oral dosing) | A Lynn, B Robertshawe | March 2023 (double dilution instructions) |
| K Simonsen | Nov 2003 (calculation of oral dose) | | | | | | | | | | | | | | | | |
| P Schmidt, B Robertshawe | December 2004 | | | | | | | | | | | | | | | | |
| A Lynn, B Robertshawe | September 2009 (guardrail) | | | | | | | | | | | | | | | | |
| A Lynn, B Robertshawe | Nov 2012 (re-order profile, discard vial) | | | | | | | | | | | | | | | | |
| A Lynn | May 2013/Aug 2015 (guardrail boluses) | | | | | | | | | | | | | | | | |
| A Lynn, B Robertshawe | October 2021 (routine review) | | | | | | | | | | | | | | | | |
| A Lynn, B Robertshawe | November 2022 (oral dosing) | | | | | | | | | | | | | | | | |
| A Lynn, B Robertshawe | March 2023 (double dilution instructions) | | | | | | | | | | | | | | | | |